ORGO (Organogenesis Holdings) Other Operating Expense: $-2.1 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ORGO Organogenesis Holdings Inc ORGO
67 GF Score
Price $2.34
GF Value $3.04
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Organogenesis Holdings Other Operating Expense?

Organogenesis Holdings ORGO +3.08% 67 Other Operating Expense is $-2.1 Mil as of Mar. 2026. GuruFocus rates ORGO with a GF Score™ of 67/100 and a GF Value™ of $3.04 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Organogenesis Holdings's Other Operating Expense for the three months ended in Mar. 2026 was $-1.0 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-2.1 Mil.

Organogenesis Holdings's quarterly Other Operating Expense declined from Sep. 2025 ($-0.4 Mil) to Dec. 2025 ($-0.5 Mil) and declined from Dec. 2025 ($-0.5 Mil) to Mar. 2026 ($-1.0 Mil).

Organogenesis Holdings's annual Other Operating Expense stayed the same from Dec. 2023 ($0.0 Mil) to Dec. 2024 ($0.0 Mil) but then declined from Dec. 2024 ($0.0 Mil) to Dec. 2025 ($-1.1 Mil).

Organogenesis Holdings Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Organogenesis Holdings's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Organogenesis Holdings Other Operating Expense Chart

Organogenesis Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -1.14

Organogenesis Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.23 -0.38 -0.54 -0.98
ORGO
67GF Score
Organogenesis Holdings Inc ORGO
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Organogenesis Holdings Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of $-2.1 Mil mean?
Organogenesis Holdings (ORGO) has a Other Operating Expense of $-2.1 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on Organogenesis Holdings and its competitors.
Is Organogenesis Holdings' Other Operating Expense too high?
Organogenesis Holdings' current Other Operating Expense is $-2.1 Mil. Overall, Organogenesis Holdings has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Organogenesis Holdings' Other Operating Expense compare to TKNO and AKBA?
Organogenesis Holdings' Other Operating Expense of $-2.1 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Drug Manufacturers company?
A good Other Operating Expense depends on the Drug Manufacturers industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Organogenesis Holdings and its competitors. Organogenesis Holdings's current Other Operating Expense is $-2.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organogenesis Holdings stock overvalued right now?
Based on GuruFocus' analysis, Organogenesis Holdings (ORGO) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.04, compared to a current price of $2.34 — trading 23% below its estimated fair value. The current Other Operating Expense is $-2.1 Mil. Organogenesis Holdings' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Organogenesis Holdings (ORGO), the current Other Operating Expense is $-2.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Organogenesis Holdings (ORGO) Overvalued in 2026?

Based on GuruFocus' analysis, Organogenesis Holdings stock appears to be undervalued. The current stock price of $2.34 is trading 23% below its estimated GF Value™ of $3.04. GuruFocus considers Organogenesis Holdings to be Modestly Undervalued.

Key valuation signals for ORGO:

  • Other Operating Expense: $-2.1 Mil
  • GF Value™: $3.04 vs. price of $2.34 (23% below fair value)
  • GF Score™: 67/100 with 5 warning signs

No single metric tells the full story. See the ORGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Organogenesis Holdings Business Description

Other Exchanges 2PQ:Germany
Address 85 Dan Road, Canton, MA, USA, 02021
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
67GF Score

Get the complete analysis for ORGO

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.34
Price
$3.04
GF Value